Skip to main content

Advertisement

Table 1 Patients’ characteristics

From: A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer

   Degarelix (Continued group) Conversion from degarelix to GnRH agonist (Changed group) p value
Number of patients    51   57  
Follow up duration (months) median (range) 19.4 (1.0–57.9) 38.8 (2.2–58.6) < 0.001
Degarelix treatment duration (months) median (range) 14 (1–52) 8 (1–39) 0.064
Age (years) median (range) 73 (49–95) 75 (50–90) 0.572
T stage T1 3 5.9% 1 1.8% 0.387
T2 10 19.6% 18 31.6%
T3 24 47.1% 26 45.6%
T4 14 27.4% 12 21.1%
N N0 29 56.9% 31 54.4% 0.796
N1 22 43.1% 26 45.6%
M M0 16 31.4% 23 40.4% 0.486
M1 35 68.6% 34 59.6%
Gleason score 6 1 2.0% 2 3.5% 0.389
7 5 9.8% 6 10.5%
8 21 41.2% 24 42.1%
9 15 29.4% 15 26.3%
10 4 7.8% 5 8.8%
unknown 5 9.8% 5 8.8%  
Initial PSA (ng/ml) Median (range) 145 (0.48–8072) 122 (5.62–9675) 0.669
PSA PSA 0–4 1 2.0% 0 0.0% 0.415
PSA4–10 5 9.8% 3 5.3%
PSA10–20 2 3.9% 5 8.8%
PSA > 20 43 84.3% 49 86.0%
Treatment CAB 48 94.1% 54 94.7% 0.889
GnRH only 3 5.9% 3 5.3%
Transition to CRPC No 37 72.5% 38 66.7% 0.508
Yes 14 27.5% 19 33.3%
% PSA decrease by degarelix median (range) −99.4% (6.6–100.0) −99.8% (47.2–100.0) 0.068
  1. Abbreviations CAB combined androgen blockade, CRPC castration resistant prostate cancer, GnRH gonadotropin releasing hormone